Novel PET tracer clearly identifies and tracks bacterial infection in lungs

January 8, 2018, Society of Nuclear Medicine and Molecular Imaging
Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 188F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, KY

Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, 2-18F-fluorodeoxysorbitol (18F-FDS), can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation. The study is the featured basic science article in the January issue of The Journal of Nuclear Medicine.

"Currently, bacterial infections can be diagnosed only after they have become systemic or have caused significant anatomical tissue damage, a stage at which they are challenging to treat owing to the high bacterial burden," explains Chin K. Ng, PhD, at the University of Louisville School of Medicine, Louisville, Kentucky.

He points out, "18F-FDG PET, a widely commercially available imaging agent, is capable of imaging infection, but it cannot distinguish infections from other pathologies such as cancer and . Therefore, there is a great need to develop imaging agents with high specificity and sensitivity. There are still no specific imaging agents that can differentiate from sterile inflammation at an early stage."

For this study, mice were inoculated with either live Klebsiella pneumoniae bacteria to induce , or the dead form of the bacteria to induce inflammation. Half of the mice with the live bacteria were imaged with PET/CT using either 18F-FDS or 18F-FDG on days 0, 1, 2 and 3 to monitor disease progression post infection. The other half were screened by bioluminescent imaging, and mice with visible infection were selected for follow-up PET/CT scans with 18F-FDS. For the inflammation group, half the mice were imaged with PET/CT using 18F-FDS and half using 18F-FDG from day 1 to day 4 post-inoculation.

While both 18F-FDS and 18F-FDG effectively tracked the degree of bacterial infection measured by bioluminescent optical imaging, only 18F-FDS was able to differentiate infection from lung inflammation.

Ng notes, "Bacterial infection represents a threat to human health, including hospital-acquired, implant-related, and multidrug-resistant infections. 18F-FDS whole-body PET/CT imaging in mice has shown to be a unique imaging technique that could differentiate infection from inflammation. This same technique could potentially be used in patients to identify infection sites and determine the bacterial infection class, so that patients could avoid taking antibiotics that are known to have no effect against specific bacteria."

He adds, "The interpretation of CT appearances of lung disorders can be complex if a differential diagnosis needs to distinguish between inflammation and infection. Thus 18F-FDS PET/CT could be initially used as a follow up after an inconclusive CT diagnosis for suspected bacterial lung infection. As proven clinical data accumulate over time, 18F-FDS PET/CT could become a new clinical standard for confirming bacterial in the lungs or other sites."

Looking ahead to making 18F-FDS clinically available, Ng states, "Since 18F-FDS can be made from 18F-FDG with one extra, simple conversion step, and sorbitol has already been approved for use in humans by the U.S. Food and Drug Administration, the approval pathway for 18F-FDS should be straightforward. 18F-FDS would be inexpensive and readily available once approved."

He also observes, "This and other new PET imaging agents demonstrate that molecular imaging and nuclear medicine can offer unique technologies for patient care and will continue to play a key influential role in healthcare."

Explore further: Glucose in the airways could increase infections in lung disease patients

More information: Junling Li et al, Validation of 2-18F-Fluorodeoxysorbitol as a Potential Radiopharmaceutical for Imaging Bacterial Infection in the Lung, Journal of Nuclear Medicine (2017). DOI: 10.2967/jnumed.117.195420

Related Stories

Glucose in the airways could increase infections in lung disease patients

January 5, 2018
People with the lung disease COPD have higher levels of glucose in their airways, researchers have shown for the first time.

Novel PET tracer identifies most bacterial infections

October 5, 2017
Stanford University medical scientists have developed a novel imaging agent that could be used to identify most bacterial infections. The study is the featured basic science article in The Journal of Nuclear Medicine's October ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

New tool may allow doctors to 'see' bacterial infection in the body

August 31, 2017
UC San Francisco scientists have developed an imaging tool that could soon allow doctors to locate and visualize bacterial infections in the body and to rule out other common causes of inflammation, such as autoimmune reactions.

Scientists find real-time imaging in mice a promising influenza study tool

May 30, 2017
Real-time imaging of influenza infection in mice is a promising new method to quickly monitor disease progression and to evaluate whether candidate vaccines and treatments are effective in this animal model, according to ...

Novel nuclear medicine test can identify kidney transplant infection

November 8, 2017
German scientists have developed a novel nuclear medicine test that can determine whether a kidney transplant patient has developed infection in the transplanted tissue. The study, which utilizes positron emission tomography/magnetic ...

Recommended for you

New hope for cystic fibrosis

October 19, 2018
A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis.

Bug guts shed light on Central America Chagas disease

October 18, 2018
In Central America, Chagas disease, or American trypanosomiasis, is spread by the "kissing bug" Triatoma dimidiata. By collecting DNA from the guts of these bugs, researchers reporting in PLOS Neglected Tropical Diseases ...

Rapid genomic sequencing of Lassa virus in Nigeria enabled real-time response to 2018 outbreak

October 18, 2018
Mounting a collaborative, real-time response to a Lassa fever outbreak in early 2018, doctors and scientists in Nigeria teamed up with researchers at Broad Institute of MIT and Harvard and colleagues to rapidly sequence the ...

Infectious disease consultation significantly reduces mortality of patients with bloodstream yeast infections

October 17, 2018
In a retrospective cohort study conducted at the University of Alabama at Birmingham Division of Infectious Diseases, patients with candidemia—a yeast infection in the bloodstream—had more positive outcomes as they relate ...

How drug resistant TB evolved and spread globally

October 17, 2018
The most common form of Mycobacterium tuberculosis (TB) originated in Europe and spread to Asia, Africa and the Americas with European explorers and colonialists, reveals a new study led by UCL and the Norwegian Institute ...

Marker may help target treatments for Crohn's patients

October 16, 2018
Crohn's disease (CD), a chronic inflammatory condition of the intestinal tract, has emerged as a global disease, with rates steadily increasing over the last 50 years. Experts have long suspected that CD likely represents ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.